AbSci Corp (ABSI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABSI POWR Grades
- ABSI scores best on the Growth dimension, with a Growth rank ahead of 54.25% of US stocks.
- The strongest trend for ABSI is in Growth, which has been heading up over the past 179 days.
- ABSI's current lowest rank is in the Quality metric (where it is better than 4.1% of US stocks).
ABSI Stock Summary
- With a one year PEG ratio of 0.49, ABSCI CORP is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.18% of US stocks.
- ABSCI CORP's stock had its IPO on July 22, 2021, making it an older stock than only 3.3% of US equities in our set.
- With a price/sales ratio of 55.02, ABSCI CORP has a higher such ratio than 96.4% of stocks in our set.
- Stocks that are quantitatively similar to ABSI, based on their financial statements, market capitalization, and price volatility, are GNTX, APLS, FOLD, LXRX, and MIRM.
- To check out ABSCI CORP's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001672688.
ABSI Valuation Summary
- In comparison to the median Healthcare stock, ABSI's price/sales ratio is 876.47% higher, now standing at 49.8.
- Over the past 19 months, ABSI's price/sales ratio has gone down 358.4.
Below are key valuation metrics over time for ABSI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABSI | 2023-01-30 | 49.8 | 1.0 | -2.5 | -1.6 |
| ABSI | 2023-01-27 | 53.4 | 1.0 | -2.7 | -1.8 |
| ABSI | 2023-01-26 | 54.0 | 1.0 | -2.8 | -1.8 |
| ABSI | 2023-01-25 | 49.1 | 0.9 | -2.5 | -1.6 |
| ABSI | 2023-01-24 | 51.1 | 1.0 | -2.6 | -1.7 |
| ABSI | 2023-01-23 | 50.6 | 1.0 | -2.6 | -1.7 |
ABSI Price Target
For more insight on analysts targets of ABSI, see our ABSI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $29.00 | Average Broker Recommendation | 1.8 (Moderate Buy) |
ABSI Stock Price Chart Interactive Chart >
ABSI Price/Volume Stats
| Current price | $3.05 | 52-week high | $9.68 |
| Prev. close | $3.36 | 52-week low | $1.94 |
| Day low | $3.01 | Volume | 840,900 |
| Day high | $3.54 | Avg. volume | 494,869 |
| 50-day MA | $2.68 | Dividend yield | N/A |
| 200-day MA | $3.38 | Market Cap | 281.80M |
AbSci Corp (ABSI) Company Bio
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI News From Around the Web
Below are the latest news stories about ABSCI CORP that investors may wish to consider to help them evaluate ABSI as an investment opportunity.
Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug CreationIn silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in biologic drug creation.VANCOUVER, Wash. and NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the expansion of its Scientific Advisory Board with three world-class scientific leaders: Victor Greiff, Ph.D., Timothy Lu, MD |
10 Penny Stocks That Will Make You A MillionaireIn this article, we will discuss the 10 penny stocks that will make you a millionaire. If you want to explore similar stocks, you can also take a look at 5 Penny Stocks That Will Make You A Millionaire. Penny stocks can be an attractive option for investors looking to get in on the stock […] |
Absci announces AI breakthrough in designing therapeutic antibodiesThe discovery could reduce the time it takes to get new drug candidates to clinic to 18-24 months from six years. |
Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AIThis breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver breakthrough therapeutics at the click of a button, for everyone. VANCOUVER, Wash. and NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, |
Have you been able to find a good deal on Absci Corporation’s shares?Absci Corporation (NASDAQ:ABSI) marked $2.26 per share on Tuesday, up from a previous closing price of $2.10. While Absci Corporation has overperformed by 7.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABSI fell by -72.44%, with highs and lows ranging from $9.68 to $1.94, whereas […] |
ABSI Price Returns
| 1-mo | 19.14% |
| 3-mo | -14.80% |
| 6-mo | -36.19% |
| 1-year | -64.45% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 45.24% |
| 2022 | -74.39% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...